RHYTHM PHARMACEUTICALS, INC. Share-based Payment Arrangement, Accelerated Cost
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Share-based Payment Arrangement, Accelerated Cost of $2.81 million for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-02.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost · last filed 2021-11-02
- RHYTHM PHARMACEUTICALS, INC. share-based payment arrangement, accelerated cost for the quarter ending 2020-06-30 was $0.00.
- RHYTHM PHARMACEUTICALS, INC. share-based payment arrangement, accelerated cost for the quarter ending 2020-03-31 was $2.81M.
| Period end | Share-based Payment Arrangement, Accelerated Cost 3 month | Share-based Payment Arrangement, Accelerated Cost 6 month | Share-based Payment Arrangement, Accelerated Cost 9 month |
|---|---|---|---|
| 2021-09-30 | $2.81M 10-Q · filed 2021-11-02 | ||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $2.81M 10-Q · filed 2021-08-03 | |
| 2020-03-31 | $2.81M 10-Q · filed 2021-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |